Share on Pinterest Novo Nordisk’s new weight loss pill, amycretin, has had promising results in an early clinical trial. Image credit: SERGEI GAPON/Getty Images. Amycretin, a new weight loss ...
The drug, called amycretin and codenamed NN9487, is a dual agonist that targets both GLP-1 and amylin and is being developed in both oral and subcutaneous injection formulations. The oral form has ...
Novo Nordisk's experimental weight-loss pill, amycretin, demonstrated safety and tolerability in early-stage trials. The pill showed significant weight reduction, with patients losing up to 13.1% of ...
There is a new chapter in Big Pharma’s billion-dollar war on obesity, as Novo Nordisk (NVO, NOVO-B.CO) and Eli Lilly (LLY) battle it out over the latest blockbuster drugs. Most Read from Fast ...